Generated by AI
Summary of Dec 4's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Summary of Oct 21's posts. Generated by AI.
Investors talking about PLRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies. Its research platform is built around integrin biology, which plays an important role in cell signaling, tissue remodeling, and disease progression. Pliant Therapeutics Inc. operates as a specialist developer within the biotechnology sector, contributing to the broader market for treatments aimed at serious, chronic, and often underserved diseases.
Website331 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about PLRX.
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership team with appointments of David Raben, M.D., as Chief Medical Officer and Craig Blanchette, Ph.D., as Senior Vice President, Research (RNAi) SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinica
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced two presentations related to PLN-101095 at the upcoming 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 4 - 8, 2026 at the Phoenix Convention Center in Phoenix, Arizona. Poster Presentations Title: Selective targeting of in